Most incidental findings on a fertility ultrasound do not change your odds of conceiving; a few change them a lot. Non-cavity-distorting intramural fibroids lower the odds of live birth after IVF by 44%, while simple functional ovarian cysts are normal byproducts of ovulation and need no treatment at all.
A scan report rarely says which category you are in — “fibroid,” “cyst,” “TSH borderline” all sound equally alarming. What matters is centimetres, location and hormone level, not the label.
How this article was researched: the ProIVF Medical Editorial Team reviewed systematic reviews, Cochrane analyses and randomized trials for each of the six findings and linked every figure to its primary source. The ProIVF Medical Advisory Board checked the draft before publication.
Do uterine fibroids affect fertility?
Sometimes, and the determining factors are location and size rather than the mere presence of a fibroid. About 4.5% to 68.6% of women have fibroids depending on the population studied and the diagnostic method used — BJOG, 2017 — so “I have a fibroid” tells you almost nothing.
When fibroids do not matter
Subserosal fibroids project outwards from the uterus and have no contact with the cavity; they are generally considered fertility-neutral.
Small intramural, non-cavity-distorting fibroids were once lumped with harmless findings — an assumption that did not survive the data.
When fibroids do matter: 44% lower odds of live birth
A meta-analysis of 15 studies and 5,029 patients found that women with non-cavity-distorting intramural fibroids had 44% lower odds of live birth after IVF (odds ratio 0.56, 95% CI 0.46–0.69) and 32% lower odds of clinical pregnancy (odds ratio 0.68, 95% CI 0.56–0.83) than women without fibroids — J Womens Health, 2020.
FIGO type 3 fibroids — intramural but contacting the endometrium — carried significantly lower live birth, clinical pregnancy and implantation rates in 1,020 patients (324 type 3 myomas, 696 controls; odds ratios 2.16, 2.06 and 1.77 favouring the no-fibroid group) — Int J Gynaecol Obstet, 2023.
“FIGO type 3 myomas are significantly associated with a lower implantation rate, cumulative pregnancy rate, and live birth rate.” — International Journal of Gynaecology and Obstetrics, 2023, PMID 37183601
Should you have a myomectomy before IVF?
There is no clean answer: the evidence is weak. A Cochrane review of surgical treatment for fibroids in subfertility included only 4 randomized trials with 442 participants, and rated the evidence for whether myomectomy improves clinical pregnancy as very low quality — with confidence intervals spanning from a 43% reduction to a six-fold increase in odds — Cochrane, 2020.
Practically, resection is a judgement call — location and size against surgical risk, recovery (typically three to six months before transfer) and adhesion risk.
Have that conversation with a surgeon who does a high volume of fertility-sparing myomectomies, not from a scan report alone.
Uterine artery embolisation deserves a separate warning: pregnancy rates after it ranged from 29% to 69%, but miscarriage reached 64% in the single randomized trial — Arch Gynecol Obstet, 2018 — generally not the first choice if you want to carry a pregnancy.
Do ovarian cysts affect fertility?
It depends almost entirely on cyst type, which the ultrasound report normally states: a functional or simple cyst is a normal stage of the ovulatory cycle; an endometrioma is a different disease.
Functional and simple cysts: usually harmless
Follicular and corpus luteum cysts form as part of normal ovulation and typically resolve on their own within one to three cycles. They neither impair fertility nor indicate surgery.
They can, however, delay treatment. The FDA labelling for clomiphene citrate lists ovarian enlargement — other than in PCOS — as a reason not to begin therapy, so a large persistent cyst can mean waiting a cycle before stimulation.
Endometriomas: worse than a simple cyst, but surgery costs ovarian reserve
An IVF study comparing 85 women with untreated endometriomas against 83 women with simple ovarian cysts found higher gonadotropin consumption in the endometrioma group (3,013 versus 2,451 IU, p = 0.001), significantly fewer oocytes retrieved (13.9 versus 16.4, p = 0.03) and a significantly lower implantation rate (19% versus 28%, p = 0.02) — while pregnancy and ongoing pregnancy rates stayed similar — Gynecol Obstet Invest, 2008.
Removing an endometrioma is not free. A meta-analysis of 30 studies found anti-Müllerian hormone — a marker of ovarian reserve — fell by 1.39 ng/mL in the short term, 1.13 ng/mL at medium term and 2.12 ng/mL long term after laparoscopic cystectomy — Gynecol Obstet Invest, 2025. Cystectomy also reduced antral follicle count (a scan proxy for remaining egg supply) more than ablation (mean difference −1.33, 95% credible interval −2.15 to −0.51) — Fertil Steril, 2022.
Should a cyst be drained before IVF?
Usually not. A Cochrane review of ovarian cyst aspiration before IVF — three studies, 339 women — found no conclusive difference in clinical pregnancy rate versus conservative management (odds ratio 1.40, 95% CI 0.67–2.94, low-quality evidence), and no difference in follicles recruited or oocytes collected — Cochrane, 2014.
“There was no conclusive evidence of a difference between the group who underwent ovarian cyst aspiration and the conservatively managed group in the clinical pregnancy rate.” — Cochrane Database of Systematic Reviews, 2014, PMID 25502626
Do endometrial polyps affect fertility?
Yes — and unlike fibroids, the evidence for removal is reasonably consistent. Polyps are focal endometrial overgrowths occupying space where an embryo needs to implant.
A systematic review of eight studies and 2,267 patients found that hysteroscopic resection of polyps smaller than 2 cm was associated with an increased clinical pregnancy rate in patients undergoing intrauterine insemination — J Minim Invasive Gynecol, 2019. Hence polypectomy before IUI or IVF is one of the few interventions in reproductive medicine with broad agreement.
Polyps also have a small but real malignant potential that argues for removal rather than watching. Across 20 studies and 9,266 women, premalignant changes were found in 0.2% to 23.8% of polyps and malignant changes in 0% to 12.9%, with the risk concentrated in postmenopausal women and in polyps that cause bleeding — Acta Obstet Gynecol Scand, 2010.
The procedure is a day-case hysteroscopy, usually without cutting the uterus; most clinics allow a transfer attempt the following cycle.
Does adenomyosis affect IVF success?
Yes, substantially — and often under-estimated because it shows no discrete lump: endometrial tissue grows inside the myometrium, leaving the uterus diffusely thickened and less receptive.
A meta-analysis found women with adenomyosis had lower live birth (odds ratio 0.59, 95% CI 0.37–0.92), lower clinical pregnancy (odds ratio 0.66, 95% CI 0.48–0.90) and lower ongoing pregnancy rates (odds ratio 0.43, 95% CI 0.21–0.88), with a higher miscarriage rate (odds ratio 2.11, 95% CI 1.33–3.33) than women without it — Reprod Sci, 2022.
A second meta-analysis of ultrasound-diagnosed adenomyosis confirmed the direction — live birth odds ratio 0.66 (95% CI 0.53–0.82), miscarriage odds ratio 1.81 (95% CI 1.35–2.44) — and found that symptomatic and diffuse adenomyosis drove the effect, while asymptomatic focal disease did not — Acta Obstet Gynecol Scand, 2023.
Treatment is difficult, so the practical step is accurate diagnosis and a realistic prognosis conversation before stimulation. Persistent implantation failure with adenomyosis is exactly what our guide to why IVF fails with good embryos addresses.
Does thyroid function affect fertility?
Yes — thyroid disease is roughly ten times more common in women than in men — Hum Reprod, 2025, hence routine testing before fertility treatment. The controversy is not whether it matters but where the treatment threshold sits.
What TSH level should trigger treatment?
The 2017 American Thyroid Association pregnancy guidelines are the reference; a large retrospective cohort confirmed a benefit from treating TSH above 4 mIU/L. But two large randomized trials then found no benefit of thyroid hormone in euthyroid women with thyroid autoantibodies — Thyroid, 2020.
A prospective study of 177 infertile women monitored 87 who conceived weekly through early pregnancy; only those with a preconception TSH above 4.5 mIU/L received thyroxine — Hum Reprod Open, 2023.
What does treatment achieve?
In a series of 69 infertile women with subclinical hypothyroidism, levothyroxine treatment was followed by conception in 84.1%, with a miscarriage rate of 29.3%. Median TSH fell from 5.46 μIU/mL to 1.25 μIU/mL, and time to pregnancy shortened from 2.8 ± 1.7 years to 0.9 ± 0.9 years — Endocr J, 2015.
Uncontrolled, it overstates what the drug alone does. The usable conclusion: TSH above roughly 4 mIU/L is worth treating before IVF; 2.5–4 mIU/L is a genuine grey zone; thyroid antibodies predict risk even when TSH is normal.
Does high prolactin affect fertility?
Yes — and this is the finding with the most reliable treatment. Prolactin suppresses gonadotropin-releasing hormone, so a persistently elevated level can stop ovulation altogether.
The strongest evidence is old but well conducted: in a randomized comparison of 459 women with hyperprolactinaemic amenorrhoea, stable normal prolactin was achieved in 83% of women on cabergoline versus 59% on bromocriptine (p < 0.001), and 72% versus 52% had ovulatory cycles or became pregnant (p < 0.001). Side effects were recorded in 68% versus 78%, and 3% versus 12% discontinued treatment because of intolerance — N Engl J Med, 1994.
A later systematic review agreed, favouring cabergoline for normalising prolactin, restoring menstruation and fewer adverse effects — Pituitary, 2011.
Practical points: measure prolactin in the morning, fasting, without recent nipple stimulation or stress; mildly elevated results are often repeated, and macroprolactin (a biologically inactive form) explains some apparent elevations.
A substantially raised prolactin also warrants checking for a prolactinoma.
Which findings need treatment before IVF — and which can wait?
Six findings, six different answers, which is why the scan report is not the decision.
| Finding | Effect on fertility | Treat before IVF? |
|---|---|---|
| Subserosal fibroid | None established | No |
| Intramural fibroid, non-cavity-distorting | 44% lower live birth odds | Discuss; evidence weak |
| FIGO type 3 fibroid | Lower implantation, pregnancy and live birth | Discuss; strongly consider |
| Functional / simple ovarian cyst | None; normal ovulatory structure | No; may delay cycle start |
| Endometrioma | Fewer oocytes, lower implantation | Often leave in place; surgery costs reserve |
| Endometrial polyp | Occupies implantation site | Yes — hysteroscopic resection |
| Adenomyosis | Live birth OR 0.59; miscarriage OR 2.11 | Optimise; no simple fix |
| TSH above ~4 mIU/L | Associated with loss and ovulatory dysfunction | Yes — levothyroxine |
| TSH 2.5–4 mIU/L | Uncertain | Grey zone; individualise |
| Prolactin elevated | Can block ovulation | Yes — dopamine agonist |
The pattern: findings occupying or distorting the cavity get treated, muscle or ovary findings mostly get watched, and hormone-signalling disorders get corrected with drugs.
What were three patients told about their scan findings?
Patient details below are composite accounts built from published case series and clinic-level patient reports. Names, ages and locations have been changed, and no individual patient is identifiable.
A 34-year-old in Seoul, one 3.2 cm fibroid, no surgery, KRW 0. Her baseline scan before a first IVF cycle reported a 3.2 cm intramural fibroid and normal uterine cavity on saline sonogram. Her clinician mapped it as FIGO type 4 and recommended proceeding without resection, because the fibroid was small, did not touch the endometrium and her AMH was 1.1 ng/mL — meaning surgical delay carried its own cost. “Everyone in my group chat with a fibroid had been operated on,” she said. “I kept asking whether not operating was the same as giving up.” She transferred a single euploid blastocyst in cycle one and is 22 weeks pregnant.
A 38-year-old in São Paulo, polypectomy, BRL 3,800. A 14 mm polyp was found after two failed IUI cycles. Resection was done as a day-case hysteroscopy, and her next IUI produced a clinical pregnancy that ended at eight weeks — a loss her doctor attributed to embryo factors, not the uterus. “The polyp was the one thing anyone could explain to me clearly,” she said. “At least that box was ticked.”
A 42-year-old in Ontario, TSH 4.1, then adenomyosis, CAD 620 in medication. Her TSH was 4.1 mIU/L and her prolactin 38 ng/mL. Both were corrected — levothyroxine and cabergoline — before her second IVF cycle. What the corrected hormones did not fix was the diffuse adenomyosis on MRI, unmentioned in the first cycle. Two transfers failed. “It was maddening that the thing they could treat in six weeks got all the attention,” she said, “and the thing they couldn’t treat got none.”
FAQ
Q: Does a fibroid mean I cannot get pregnant naturally?
No. Most fibroids are compatible with natural conception, and the evidence for harm is strongest in specific locations.
Intramural fibroids that do not distort the cavity were associated with 44% lower live birth odds in IVF cycles; subserosal fibroids showed no established effect.
The American College of Obstetricians and Gynecologists maintains a patient-facing overview of infertility evaluation, ACOG.
Q: Can an ovarian cyst stop me ovulating?
Rarely. Functional cysts are produced by ovulation itself, so they are a sign that ovulation is happening.
An IVF study of 83 women with simple cysts measuring 10–35 mm began stimulation without aspirating them, and a Cochrane review of 339 women found aspiration made no conclusive difference to clinical pregnancy rate versus conservative management (odds ratio 1.40, 95% CI 0.67–2.94).
Q: Do polyps cause miscarriage?
They are associated with lower implantation and pregnancy rates, and removal is supported by a review of eight studies covering 2,267 patients. Whether polyps cause pregnancy loss specifically is less well established than their effect on implantation.
Removal also removes a small but real cancer risk: across 20 studies and 9,266 women, premalignant change appeared in 0.2% to 23.8% of polyps and malignant change in 0% to 12.9%, concentrated in postmenopausal women and those with bleeding.
Q: Is adenomyosis treatable before IVF?
There is no simple fix: live birth odds are around 0.59 and miscarriage odds 2.11 in women with adenomyosis, with symptomatic and diffuse disease affected most.
GnRH agonist suppression and a frozen transfer with a prepared lining are the most common strategies; accurate diagnosis before stimulation matters more than any single drug.
Q: What TSH level is too high for IVF?
A large retrospective cohort supported treating TSH above 4 mIU/L — the practical threshold most clinics use. Levels of 2.5–4 mIU/L remain contested: two large randomized trials found no benefit in euthyroid women with thyroid antibodies, so that range is genuinely individual.
Q: Can high prolactin be treated easily?
Yes — a 459-woman randomized trial found cabergoline normalised prolactin in 83% versus 59% on bromocriptine, with 72% versus 52% achieving ovulation or pregnancy.
Treatment is oral, usually weekly, and generally well tolerated.
Q: Should I have surgery for a fibroid before starting IVF?
Ask for the FIGO classification first: a Cochrane review found only four randomized trials with 442 participants and rated the evidence on whether myomectomy improves pregnancy as very low quality, so a decision rests on location, size, ovarian reserve and the specific risk surgery would carry for you.
Q: Do these findings affect men’s fertility too?
Only indirectly. Fibroids, cysts, polyps, adenomyosis and prolactin disorders are female-factor findings, though thyroid disease can affect sperm production.
But don’t overlook the male side — male factors account for about 50% of couples’ infertility (sole cause in 20%, contributing in 30%), with evaluation on a separate pathway.
Planning your next step
A scan report lists findings; it does not rank them. The work is deciding which of them actually sits between you and a pregnancy.
- Ask for the FIGO classification of any fibroid, not just its size — type 3 and cavity-distorting types are the ones that matter most.
- Ask whether your cyst is functional, simple or an endometrioma. Simple cysts are watched; endometriomas are usually left alone — surgery costs ovarian reserve.
- Treat what occupies the cavity. Polyps should be resected; the evidence for that is the firmest in this entire article.
- Get TSH and prolactin onto one page. A TSH above roughly 4 mIU/L and an elevated prolactin are both correctable in weeks and both worth correcting before a transfer.
- Do not accept “we’ll see” about adenomyosis. Live birth odds around 0.59 deserve a concrete strategy conversation before stimulation starts.
- Check the tubes too. These findings often coexist with tubal damage, and hydrosalpinx is one of the few factors with a clear surgical answer — tubal factor guide.
To choose where these findings are assessed and treated, browse verified clinic profiles covering published success rates, pricing and reviews, or contact our team to match your diagnosis to clinics that treat it routinely; the guide to choosing an IVF clinic covers questions for a first visit, and the PCOS guide and endometriosis guide cover two heavily overlapping conditions.
Disclaimer: this article is for education only and is not medical advice. Every finding above requires individual assessment by a licensed clinician; do not use this article to decide for or against surgery or medication.
Odds ratios and incidence figures quoted are population-level results and cannot predict any individual’s outcome. Do not start, stop or adjust medication without consulting your clinical team.
Written by the ProIVF Medical Editorial Team, reviewed by the ProIVF Medical Advisory Board; figures come from the linked primary sources.
Last updated: October 4, 2026
